Concepedia

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Howard Gurney, Yen‐Hwa Chang, Jae‐Lyun Lee,

The Lancet Oncology · 2022 · 278 citations · 16 references

DOIFull text

Open access

Concepts

References

16

Prognostic significance of morphologic parameters in renal cell carcinoma

Susan Fuhrman, Larry C. Lasky, Catherine Limas · The American Journal of Surgical Pathology · 1982 · 2.7K citations

, , +16

Discrete Sequential Boundaries for Clinical Trials

K. K. Gordon Lan, David L. DeMets · Biometrika · 1983 · 1.7K citations

, , +10

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Bernard Escudier, Camillo Porta, Manuela Schmidinger et al. · Annals of Oncology · 2019 · 1.2K citations · Full text

, , +14

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma

Bradley C. Leibovich, Michael L. Blute, John C. Cheville et al. · Cancer · 2003 · 831 citations

, , +17

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Alain Ravaud, Robert J. Motzer, Hardev Pandha et al. · New England Journal of Medicine · 2016 · 777 citations

, , +17